OVID (STOCKS)
Ovid Therapeutics Inc. Common Stock
$2.830000
+0.030000 (+1.07%)
Prev close: $2.800000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Margaret Alexander
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $526.33M
- Employees
- 23
- P/E (TTM)
- -11.17
- P/B (TTM)
- 2.21
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.12 | $-0.12 | +0.0027 | +2.20% |
|
Dec 2025 (Q4)
|
$0.06 | $-0.12 | +0.1814 | +149.42% |
|
Sep 2025 (Q3)
|
$-0.17 | $-0.15 | -0.0171 | -11.18% |
|
Jun 2025 (Q2)
|
$-0.06 | $-0.16 | +0.1049 | +63.61% |
Financial Statements
| Revenues | $7.12M |
| Operating Expenses | $54.86M |
| Research and Development | $30.10M |
| Other Operating Expenses | $24.75M |
| Operating Income/Loss | -$47.74M |
| Income/Loss From Continuing Operations After Tax | -$24.17M |
| Income/Loss From Continuing Operations Before Tax | -$24.17M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$24.17M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$24.17M |
| Net Income/Loss Available To Common Stockholders, Basic | -$24.17M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$272.00K |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $225.63M |
| Current Assets | $160.15M |
| Cash | $165.60M |
| Noncurrent Assets | $65.48M |
| Fixed Assets | $217.00K |
| Other Non-current Assets | $65.27M |
| Liabilities | $27.36M |
| Current Liabilities | $15.75M |
| Accounts Payable | $8.88M |
| Wages | $822.00K |
| Other Current Liabilities | $6.05M |
| Noncurrent Liabilities | $11.61M |
| Equity | $198.27M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $198.27M |
| Liabilities And Equity | $225.63M |
| Net Cash Flow From Operating Activities | -$41.95M |
| Net Cash Flow From Operating Activities, Continuing | -$41.95M |
| Net Cash Flow From Investing Activities | -$49.01M |
| Net Cash Flow From Investing Activities, Continuing | -$49.01M |
| Net Cash Flow From Financing Activities | $164.18M |
| Net Cash Flow From Financing Activities, Continuing | $164.18M |
| Net Cash Flow | $73.22M |
| Net Cash Flow, Continuing | $73.22M |
| Comprehensive Income/Loss | -$24.52M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$24.52M |
| Other Comprehensive Income/Loss | -$19.84M |